Business Description
CTI BioPharma Corp
NAICS : 325412
SIC : 2834
ISIN : US12648L6011
Description
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.21 | |||||
| Equity-to-Asset | -0.23 | |||||
| Debt-to-Equity | -1.93 | |||||
| Debt-to-EBITDA | -0.98 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -27.01 | |||||
| Beneish M-Score | 26.13 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 100.9 | |||||
| 3-Year EBITDA Growth Rate | -0.8 | |||||
| 3-Year EPS without NRI Growth Rate | -5.5 | |||||
| 3-Year FCF Growth Rate | -24.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | |||||
| Quick Ratio | 1.26 | |||||
| Cash Ratio | 0.86 | |||||
| Days Inventory | 56.65 | |||||
| Days Sales Outstanding | 57.35 | |||||
| Days Payable | 196.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.1 | |||||
| Shareholder Yield % | -2.07 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.11 | |||||
| Operating Margin % | -71.18 | |||||
| Net Margin % | -91.38 | |||||
| FCF Margin % | -108.2 | |||||
| ROA % | -55.16 | |||||
| ROIC % | -93.31 | |||||
| ROC (Joel Greenblatt) % | -1334.9 | |||||
| ROCE % | -81.51 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.88 | |||||
| EV-to-EBIT | -22.8 | |||||
| EV-to-EBITDA | -23.78 | |||||
| EV-to-Revenue | 15.69 | |||||
| EV-to-FCF | -14.44 | |||||
| Earnings Yield (Greenblatt) % | -4.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CTI BioPharma Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 72.512 | ||
| EPS (TTM) (€) | -0.555 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 2.78781 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 2.78781 - 2.78781 | ||
| Shares Outstanding (Mil) | 131.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CTI BioPharma Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CTI BioPharma Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
CTI BioPharma Corp Frequently Asked Questions
What is CTI BioPharma Corp(LTS:0RLB)'s stock price today?
The current price of LTS:0RLB is €2.79. The 52 week high of LTS:0RLB is €2.79 and 52 week low is €2.79.
When is next earnings date of CTI BioPharma Corp(LTS:0RLB)?
The next earnings date of CTI BioPharma Corp(LTS:0RLB) is 2024-08-08 Est..
Does CTI BioPharma Corp(LTS:0RLB) pay dividends? If so, how much?
CTI BioPharma Corp(LTS:0RLB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers